Compare VZLA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | OGN |
|---|---|---|
| Founded | 2017 | 1923 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | VZLA | OGN |
|---|---|---|
| Price | $3.87 | $7.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $14.10 |
| AVG Volume (30 Days) | ★ 13.5M | 6.1M |
| Earning Date | 12-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $6,301,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.69 | $6.18 |
| 52 Week High | $7.19 | $17.23 |
| Indicator | VZLA | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 39.51 |
| Support Level | $3.58 | $7.74 |
| Resistance Level | $5.47 | $8.48 |
| Average True Range (ATR) | 0.46 | 0.39 |
| MACD | -0.25 | -0.17 |
| Stochastic Oscillator | 8.17 | 3.70 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.